Evidence map›Paper›PMID 39439289›Full record

ArticleAlzheimer's & dementia : the journal of the Alzheimer's Association2024

Microscopy assessment of a fluorescence [

Rodolfo G Gatto, Youssef Hossam, R Ross Reichard, Val J Lowe, Jennifer L Whitwell, Keith A Josephs

Abstract read
In one paragraph

Article in Alzheimer's & dementia : the journal of the Alzheimer's Association, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Microscopy assessment of a fluorescence [Alzheimer's & dementia : the journal of the Alzheimer's Association · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Rodolfo G GattoDepartment of Neurology, Mayo Clinic, Rochester, Minnesota, USA.ORCID 0000-0003-2170-6662
Youssef HossamDepartment of Neurology, Mayo Clinic, Rochester, Minnesota, USA.
R Ross ReichardDepartment of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, USA.
Val J LoweDepartment of Radiology, Mayo Clinic, Rochester, Minnesota, USA.
Jennifer L WhitwellDepartment of Radiology, Mayo Clinic, Rochester, Minnesota, USA.
Keith A JosephsDepartment of Neurology, Mayo Clinic, Rochester, Minnesota, USA.

Funding

Longitudinal multi-modality imaging in progressive apraxia of speech (Diversity Supplement)R01DC012519 · NIDCD · MAYO CLINIC ROCHESTER · PI Jennifer Louise Whitwell · 2013 to 2026
$7.2M
Molecular and structural imaging in atypical Alzheimer's disease: a longitudinal studyR01AG050603 · NIA · MAYO CLINIC ROCHESTER · PI WHITWELL, JENNIFER LOUISE · 2016 to 2025
$5.9M
Longitudinal Multi-modal Imaging in Progressive Supranuclear Palsy SyndromesR01NS089757 · NINDS · MAYO CLINIC ROCHESTER · PI JOSEPHS, KEITH A, WHITWELL, JENNIFER LOUISE · 2015 to 2024
$5.6M
The neurobiology of two distinct types of progressive apraxia of speechR01DC014942 · NIDCD · MAYO CLINIC ROCHESTER · PI Keith A Josephs, Rene Lynn Utianski · 2017 to 2026
$4.9M
Flortaucipir PET and histopathology in frontotemporal lobar degeneration and Alzheimer’s diseaseRF1NS112153 · NINDS · MAYO CLINIC ROCHESTER · PI JOSEPHS, KEITH A, WHITWELL, JENNIFER LOUISE · 2021 to 2021
$1.2M
Flortaucipir PET and histopathology in frontotemporal lobar degeneration and Alzheimer’s diseaseR01NS112153 · NINDS · MAYO CLINIC ROCHESTER · PI JOSEPHS, KEITH A, WHITWELL, JENNIFER LOUISE · 2024 to 2025
$767k
NIA NIH HHS R01 AG050603NIDCD NIH HHS R01 DC012519NIDCD NIH HHS R01 DC014942NIH HHS R01-AG50603NIH HHS R01-DC12519NIH HHS R01-DC14942NIH HHS R01-NS89757NIH HHS RF1-NS112153NINDS NIH HHS R01 NS089757NINDS NIH HHS R01 NS112153NINDS NIH HHS RF1 NS112153
6 · The paper itself

Abstract

background[

methodWe assessed T726 binding to amyloid beta (Aβ) and different tau isoforms in nine subjects (one control, three with Alzheimer's disease [AD], and five with FTLD) with different 3R and 4R tauopathies using fluorescence confocal microscopy.

resultsT726 did not colocalize with Aβ but showed significant co-localization with PHF tau in AD. We also observed some, albeit limited, co-localization of T726 with 3R and 4R tau lesions in FTLD. DISCUSSION: This study's findings support FTP binding to some 3R and 4R tau lesions in FTLD. Further studies are needed to understand the biology of why FTP binds some but not all FTLD tau lesions. HIGHLIGHTS: Flortaucipir analog (T726) showed significant co-localization with paired helical filament (PHF) tau in Alzheimer's disease (AD). Colocalization between T726 with 3R and 4R tau lesions was observed in frontotemporal lobar degeneration (FTLD). Not all 4R tau lesions bind to T726 across different FTLD brain regions.

Indexed as

Alzheimer DiseaseCarbolinestau ProteinsAgedAged, 80 and overAmyloid beta-PeptidesBrainFemaleFrontotemporal Lobar DegenerationHumansMaleMiddle AgedPositron-Emission TomographyProtein Isoforms7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indoleAmyloid beta-PeptidesCarbolinesProtein Isoformstau Proteinsflortaucipirfrontotemporal lobar degenerationPick's diseaseprogressive supranuclear palsyT726tauopathy

Identifiers

PMID39439289
PMCPMC11667531

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.